Ornithine
14 benefits mapped to clinical evidence across supplements.
Dose per serving from products
54 products in our catalogue print how much Ornithine a serving holds.
Most common: 250 mg to 500 mg, 41% of 54 products.
| Dose per serving | Products |
|---|---|
| 10 mg or less | 2 |
| 10 mg to 25 mg | 2 |
| 25 mg to 50 mg | 2 |
| 50 mg to 100 mg | 3 |
| 100 mg to 250 mg | 8 |
| 250 mg to 500 mg | 22 |
| 500 mg to 1 g | 6 |
| 1 g to 2.5 g | 7 |
| over 2.5 g | 2 |
Dose per serving from research
13 study groups in 8 studies say how much Ornithine participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 5 g to 10 g and 10 g to 25 g, 31% of 13 study groups each.
| Daily dose | Study groups |
|---|---|
| 250 mg to 500 mg | 3 |
| 500 mg to 1 g | 0 |
| 1 g to 2.5 g | 0 |
| 2.5 g to 5 g | 0 |
| 5 g to 10 g | 4 |
| 10 g to 25 g | 4 |
| 25 g to 50 g | 2 |
Benefit Evidence
Ornithine â; lymphocytes â
Infections â; stay â
Immune markers â
Nitrogen balance +127g
Muscle protein synthesis +20%
Protein breakdown reduced
Nitrogen balance +127g
Muscle protein synthesis +20%
Protein breakdown reduced
Research sources
Illness recovery (19)
- Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial
PubMed ID: 7874893
Arginineâcontaining enteral formula associated with shorter hospital stays (clinical recovery outcome; formula multiâcomponent).
- Effect of a specialized amino acid mixture on human collagen deposition
PubMed ID: 12192323
Arginineâcontaining mix (raising ornithine) increased collagen deposition in implanted wound models in older adults (supports tissue recovery).
- Effects of long-term continuous use of immune-enhancing enteral formula on nutritional and immunologic status in non-surgical patients
PubMed ID: 16815486
Longâterm enteral immuneâenhancing formula raised IGFâI while increasing plasma arginine/ornithine (multiânutrient intervention showing hormonal change).
- Efficacy and safety of ornithine alpha-ketoglutarate in heel pressure ulcers in elderly patients: results of a randomized controlled trial
PubMed ID: 19621198
Ornithineâcontaining OKG modestly accelerated early wound closure in smaller heel ulcers (randomized trial subgroup effect).
- Ornithine alpha-ketoglutarate improves wound healing in severe burn patients: a prospective randomized double-blind trial versus isonitrogenous controls
PubMed ID: 10890617
OKG shortened wound healing time and reduced protein hypercatabolism in burn patients.
- Nutritional and clinical efficacy of ornithine alpha-ketoglutarate in severe burn patients
PubMed ID: 10601539
Doubleâblind trial in severe burns: OKG preserved weight and greatly improved nitrogen balanceâstrong recovery signal.
- A randomized controlled trial of the influence of the mode of enteral ornithine alpha-ketoglutarate administration in burn patients
PubMed ID: 9482764
Enteral OKG in burn patients markedly improved nitrogen balance and shortened time to last graft.
- A two-centre, randomized, double-blind trial of ornithine oxoglutarate in 194 elderly, ambulatory, convalescent subjects
PubMed ID: 7976777
OGO improved appetite, weight and independence in elderly convalescentsâpractical recovery benefit.
- Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes
PubMed ID: 35238476
Clear doseâdependent ammonia lowering and shorter time to ammonia normalization (statistically significant)âmechanistically supportive of faster biochemical/clinical recovery from hyperammonemia.
- A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda
PubMed ID: 29471865
Ugandan NECT trial: non-inferior cure and fewer lab AEs â supports efficient clinical recovery in that disease context.
- Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial
PubMed ID: 19559476
NECT produced non-inferior cure rates for late-stage sleeping sickness â robust evidence of clinical recovery with eflornithine-based therapy.
- Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo
PubMed ID: 17990225
Eflornithine-containing regimens produce high cure rates for second-stage HAT â clear clinical recovery endpoint (disease context).
- Randomised controlled trial of the effects of L-ornithine on stress markers and sleep quality in healthy workers
PubMed ID: 24889392
L-ornithine reduced cortisol/DHEA-S ratio (stress hormone balance) in workers â supports modulation of recovery/stress hormones.
- L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial
PubMed ID: 34822189
Large RCT: IV LOLA markedly increased recovery rates, shortened recovery time and reduced 28-day mortality in severe HE.
- Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo
PubMed ID: 29727385
6âmonth oral LOLA reduced HE recurrence and improved neurophysiology â supports faster/stronger longâterm recovery.
- L-ornithine L-aspartate in bouts of overt hepatic encephalopathy
PubMed ID: 28749571
IV LOLA added to standard care sped recovery from overt HE (mean recovery time reduced â0.6 days).
- Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS
PubMed ID: 24832463
Short prophylactic LOLA after TIPSS reduced ammonia rises and improved mental tests during early postâprocedure period.
- Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy
PubMed ID: 22078345
LOLA added to standard care in cirrhotics led to more patients improving and shorter hospital stays.
- Early enteral supplementation with key pharmaconutrients improves Sequential Organ Failure Assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double-blind trial
PubMed ID: 18007263
Early pharmaconutrition speeded organâfunction recovery (SOFA decline) while increasing arginine/ornithine (multiânutrient intervention with clinical effect).
Endurance (18)
- A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy
PubMed ID: 21646910
Oral LOLA lowered arterial ammonia and aided recovery from mild HE vs no treatment.
- Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy
PubMed ID: 22078345
LOLA adjunct improved encephalopathy rates and shortened hospitalization; arterial ammonia data supportive though modest.
- Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial
PubMed ID: 25038208
LOLA improved neurophysiologic endpoints in MHE with reported ammonia decreases vs placebo (numeric data partially NR).
- Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS
PubMed ID: 24832463
Prophylactic short-course LOLA after TIPSS markedly reduced fasting and post-prandial ammonia rises vs control.
- L-ornithine L-aspartate in bouts of overt hepatic encephalopathy
PubMed ID: 28749571
Multicenter IV LOLA RCT: venous ammonia reduced and faster recovery from overt HE vs placebo.
- Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo
PubMed ID: 29727385
6âmonth RCT: oral LOLA markedly lowered arterial ammonia vs placebo and reduced HE recurrence â strongest support for ammonia lowering.
- Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding
PubMed ID: 30079329
LOLA given early after variceal bleed substantially reduced incidence/severity of HE (ammonia-related outcome).
- [Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels]
PubMed ID: 24025143
Ornithineâaspartate + naloxone trial in hepatic encephalopathy produced clear reductions in blood ammonia.
- [Effect of Acupuncture at Thirteen Evil Acupoints on Liver Function, and the Contents of Blood Ammonia and β-endorphin in Patients with Hepatic Encephalopathy]
PubMed ID: 29072017
Study including ornithineâaspartate as part of HE therapy showed ammonia reductions versus control.
- An Open-Label Randomized Controlled Non-Inferiority Trial of Arginine Glutamate Injection for the Treatment of Mild Hepatic Encephalopathy
PubMed ID: 40545706
Arginine-glutamate was non-inferior to LOLA in improving ammonia and clinical HE outcomesârelevant ammonia-lowering evidence.
- Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study
PubMed ID: 9185752
7-day IV LOLA lowered fasting/postprandial ammonia and improved psychometrics in chronic HE.
- Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study
PubMed ID: 9625322
Two-week oral LOLA reduced ammonia and improved clinical/psychometric outcomes vs placebo.
- [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy]
PubMed ID: 15958319
IV LOLA added to standard care decreased ammonia and improved hepatic measures in cirrhotics.
- L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial
PubMed ID: 34822189
IV LOLA RCT reported greater reductions in blood ammonia alongside clinical benefit and lower mortality in severe HE.
- Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study
PubMed ID: 38789596
Comparative oral vs IV LOLA study: both routes produced significant ammonia reductions over 5 days.
- Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial
PubMed ID: 33069881
Ornithineâphenylacetate showed ammonia lowering in some analyses and faster improvement in a centralâlab hyperammonemia subgroupâmoderate evidence for reducing ammonia buildup.
- Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes
PubMed ID: 35238476
Strong PK/PD evidence: doseâdependent, statistically significant plasma ammonia reductions and shorter time to ammonia normalizationâhighly relevant to preventing ammonia buildup.
- L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy
PubMed ID: 18983791
IV LOLA improved ammonia handling and clinical encephalopathy signs in overt HE.
Liver support (17)
- [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy]
PubMed ID: 15958319
IV LOLA added to standard care decreased ammonia and improved liver-related measures in cirrhotics.
- Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study
PubMed ID: 9625322
Oral LOLA reduced ammonia and improved liver-associated encephalopathy indices.
- Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study
PubMed ID: 9185752
IV LOLA improved ammonia and clinical measures in chronic HEâstrong support for liver-related benefit.
- An Open-Label Randomized Controlled Non-Inferiority Trial of Arginine Glutamate Injection for the Treatment of Mild Hepatic Encephalopathy
PubMed ID: 40545706
Arginine-glutamate was non-inferior to LOLA for improving mild HE and lowering ammoniaârelevant to liver function support.
- [Effect of Acupuncture at Thirteen Evil Acupoints on Liver Function, and the Contents of Blood Ammonia and β-endorphin in Patients with Hepatic Encephalopathy]
PubMed ID: 29072017
Study including ornithineâaspartate as part of standard therapy for HE produced better biochemical/liver outcomes.
- Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS
PubMed ID: 24832463
Short prophylactic LOLA after TIPSS markedly reduced ammonia rises â practical liver/prophylactic support.
- L-ornithine L-aspartate in bouts of overt hepatic encephalopathy
PubMed ID: 28749571
Multicenter RCT: IV LOLA sped HE recovery and lowered ammonia as an add-on to standard care.
- Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo
PubMed ID: 29727385
Well-powered 6âmonth RCT: oral LOLA reduced recurrence of overt HE, lowered arterial ammonia and improved neuro tests in cirrhotics â strong liver-related benefit.
- Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding
PubMed ID: 30079329
Early prophylactic LOLA after variceal bleed reduced incidence and severity of overt HE â clinically relevant liver protection.
- L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial
PubMed ID: 34822189
Large double-blind RCT: IV LOLA added to usual care for severe HE improved HE grade, reduced time to recovery and decreased 28âday mortality; supports liver/HE therapy.
- Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study
PubMed ID: 38789596
Small trial: oral and IV LOLA produced comparable ammonia drops and HE improvement.
- Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes
PubMed ID: 35238476
Strong PK/PD evidence that OP doseâdependently lowers plasma ammonia and speeds normalizationâdirectly relevant to managing hyperammonemia from liver dysfunction.
- Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial
PubMed ID: 25038208
LOLA improved neurophysiologic endpoints in minimal HE; ammonia decrease reported â relevant to liver encephalopathy care.
- [Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels]
PubMed ID: 24025143
Ornithineâaspartate plus naloxone lowered blood ammonia and improved cognition in hepatic encephalopathy.
- Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy
PubMed ID: 22078345
LOLA added to standard care improved encephalopathy rates and shortened hospitalization in cirrhotics.
- A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy
PubMed ID: 21646910
Oral LOLA improved mild HE recovery and lowered ammonia vs no treatment â supports hepatic encephalopathy management.
- L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy
PubMed ID: 18983791
IV LOLA improved ammonia handling and clinical encephalopathy in overt HE patients.
Detoxification (15)
- Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS
PubMed ID: 24832463
Post-TIPSS prophylactic LOLA markedly reduced fasting/post-prandial ammonia rises â direct detox effect.
- [Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels]
PubMed ID: 24025143
Ornithineâaspartate lowered blood ammonia and improved cognition in HE â detoxification benefit.
- [Effect of Acupuncture at Thirteen Evil Acupoints on Liver Function, and the Contents of Blood Ammonia and β-endorphin in Patients with Hepatic Encephalopathy]
PubMed ID: 29072017
Adjunctive therapy including ornithineâaspartate improved ammonia and liver markers (detox relevance).
- An Open-Label Randomized Controlled Non-Inferiority Trial of Arginine Glutamate Injection for the Treatment of Mild Hepatic Encephalopathy
PubMed ID: 40545706
Arginine-glutamate matched LOLA for ammonia reduction in mild HEâsupports detox equivalence of ornithine-containing therapy.
- Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study
PubMed ID: 9185752
IV LOLA lowered ammonia and improved encephalopathyâevidence for enhanced detoxification of ammonia.
- Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study
PubMed ID: 9625322
Oral LOLA reduced ammonia and improved neuropsychiatric signsâsupports detox function.
- [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy]
PubMed ID: 15958319
IV LOLA plus routine care decreased ammoniaâevidence of improved detox in cirrhotics.
- L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy
PubMed ID: 18983791
IV LOLA improved ammonia handling in overt HEâsupports detoxification capacity.
- A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy
PubMed ID: 21646910
Oral LOLA lowered ammonia and improved recovery in mild HE vs no treatment.
- Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial
PubMed ID: 25038208
LOLA improved neurophysiology in MHE and reportedly decreased ammonia vs placebo â supports detoxification.
- L-ornithine L-aspartate in bouts of overt hepatic encephalopathy
PubMed ID: 28749571
IV LOLA sped recovery from OHE and reduced ammonia â consistent with improved detoxification.
- Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo
PubMed ID: 29727385
Oral LOLA lowered arterial ammonia substantially over 6 months â demonstrates improved ammonia detoxification in cirrhotics.
- L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial
PubMed ID: 34822189
IV LOLA RCT: greater reductions in blood ammonia and inflammatory markers â supports detox (ammonia clearance) and reduced systemic toxin burden.
- Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: A randomized double-blind placebo-controlled trial
PubMed ID: 36655410
Pyridoxamine reduced plasma methylglyoxal and proteinâbound MGâH1 (an imidazolonylâornithine AGE) and lowered some adhesion molecules â direct biochemical reduction of an ornithineâcontaining AGE supports a detoxification effect on reactive metabolites.
- Pharmacokinetics/pharmacodynamics of L-ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes
PubMed ID: 35238476
Demonstrated doseâdependent plasma ammonia reduction and faster ammonia normalization; mechanistically strong evidence for improving ammonia detoxification.
Mental clarity (13)
- L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy
PubMed ID: 18983791
IV LOLA improved clinical signs and ammonia handling in overt HE, with improved mental state.
- Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study
PubMed ID: 9625322
Oral LOLA reduced ammonia and improved NCT and mental state vs placebo.
- Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study
PubMed ID: 9185752
IV LOLA improved ammonia and psychometric tests in cirrhosisâstrong evidence for improved cognition/clarity.
- An Open-Label Randomized Controlled Non-Inferiority Trial of Arginine Glutamate Injection for the Treatment of Mild Hepatic Encephalopathy
PubMed ID: 40545706
Arginine-glutamate was non-inferior to LOLA for improving mild HE and cognitionâsupports cognitive benefit of ornithine-containing therapy.
- [Effect of Acupuncture at Thirteen Evil Acupoints on Liver Function, and the Contents of Blood Ammonia and β-endorphin in Patients with Hepatic Encephalopathy]
PubMed ID: 29072017
Acupuncture + standard therapy (including ornithineâaspartate) improved cognitive outcomes in HE patients.
- [Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels]
PubMed ID: 24025143
Ornithineâaspartate + naloxone in hepatic encephalopathy lowered ammonia and improved cognitive scores.
- Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy
PubMed ID: 22078345
LOLA added to standard care improved encephalopathy scores and psychometry vs placebo.
- Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial
PubMed ID: 25038208
Randomized trial in MHE: LOLA improved CFF and neuropsychometric endpoints vs placebo.
- Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS
PubMed ID: 24832463
Prophylactic LOLA after TIPSS reduced ammonia rise and improved cognitive tests vs no LOLA.
- L-ornithine L-aspartate in bouts of overt hepatic encephalopathy
PubMed ID: 28749571
Large IV LOLA RCT in overt HE: faster clinical recovery and ammonia lowering with better daily HE grades â supports clearer cognition.
- Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo
PubMed ID: 29727385
6âmonth oral LOLA RCT: marked improvements in CFF and PHES (neuropsych) and lower ammonia â strong evidence for improved mental function.
- The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition
PubMed ID: 21339541
In malnourished cirrhotics, LOLA improved critical flicker frequency (a cognitive measure) over 2 weeks.
- A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy
PubMed ID: 21646910
Oral LOLA improved mild HE recovery, lowered ammonia and improved QoL/psychometry vs no treatment.
Metabolism (10)
- Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer
PubMed ID: 11801552
Topical DFMO reduced actinic keratoses and lowered tissue spermidine and p53âpositive cells â strong local metabolic and clinical effects on polyamine metabolism.
- A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers
PubMed ID: 12374678
12âmonth oral DFMO reduced urinary total polyamines by ~28% in highârisk women â clear modulation of polyamine metabolism.
- Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine
PubMed ID: 11142412
Six months topical DFMO reduced actinic keratoses (~24%) and lowered skin spermidine with no systemic exposure â clear local metabolic and clinical effects.
- Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine
PubMed ID: 8478959
Phase I DFMO study showed doseâdependent inhibition of induced skin ODC activity with clear pharmacodynamics; relevant to ornithine/polyamine metabolism.
- Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention
PubMed ID: 21930798
Genetic association near ODC affects adenoma risk and aspirin response â indicates ODC/polyamine pathway relevance to human metabolism.
- Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients
PubMed ID: 20798393
Genotype-stratified analysis showed DFMO+sulindac lowered tissue polyamines and adenoma risk â metabolism/polyamine pathway evidence.
- Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial
PubMed ID: 18841250
Phase III DFMO+sulindac trial produced large reductions in adenoma recurrence and demonstrates strong biological activity on polyamine metabolism.
- The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial
PubMed ID: 18268112
Year-long DFMO lowered prostate putrescine and blunted prostate growth â clear effect on polyamine metabolism.
- Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas
PubMed ID: 12631596
Randomized trial adding DFMO to PCV improved PFS/OS in anaplastic glioma â clinically meaningful outcomes likely mediated via polyamine metabolic effects.
- Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma
PubMed ID: 20538001
Large randomized DFMO+sulindac trial produced sustained suppression of tissue polyamines (downstream of ornithine) that predicted chemopreventive benefit â direct effect on polyamine metabolism.
Tissue repair (8)
- A randomized controlled trial of the influence of the mode of enteral ornithine alpha-ketoglutarate administration in burn patients
PubMed ID: 9482764
Bolus OKG markedly shortened wound healing time in burn patients (large clinical effect).
- Nutritional and clinical efficacy of ornithine alpha-ketoglutarate in severe burn patients
PubMed ID: 10601539
Strong RCT in severe burns: OKG preserved weight, improved nitrogen balance and visceral proteinsâsupports muscle repair.
- Ornithine alpha-ketoglutarate improves wound healing in severe burn patients: a prospective randomized double-blind trial versus isonitrogenous controls
PubMed ID: 10890617
Randomized trial: OKG group had substantially shorter woundâhealing times vs control.
- Efficacy and safety of ornithine alpha-ketoglutarate in heel pressure ulcers in elderly patients: results of a randomized controlled trial
PubMed ID: 19621198
OKG (ornithineâcontaining) modestly accelerated early wound area reduction and closure rates in smaller heel ulcers (randomized multicenter data, subgroup effect).
- Effect of a specialized amino acid mixture on human collagen deposition
PubMed ID: 12192323
Arginineâcontaining amino acid mix increased collagen deposition in implanted wound models (supports healing/repair).
- L-ornithine supplementation in periodontitis treatment yields greater benefits than L-arginine after one year: Part II of a randomized controlled pilot study
PubMed ID: 40614877
L-ornithine adjunct to periodontal care produced larger long-term clinical improvements in bleeding and macrophage markersâevidence for faster/local healing.
- Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo
PubMed ID: 17990225
Eflornithine regimens high cure rates for HAT demonstrate healing from infection; not relevant to general tissue healing via supplementation.
- Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial
PubMed ID: 19559476
NECT regimen cured late-stage HAT â clinical resolution of severe disease = definitive healing in that context (not general wound healing).
Immune support (5)
- L-ornithine supplementation in periodontitis treatment yields greater benefits than L-arginine after one year: Part II of a randomized controlled pilot study
PubMed ID: 40614877
Adjunctive L-ornithine in periodontitis increased macrophage markers and reduced bleedingâdirect immune-modulatory evidence.
- Randomized clinical trial of the effects of perioperative use of immune-enhancing enteral formula on metabolic and immunological status in patients undergoing esophagectomy
PubMed ID: 17653789
Perioperative immuneâenhancing enteral feeding (including ornithineâraising ingredients) increased lymphocyte counts after esophagectomy.
- Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial
PubMed ID: 7874893
ICU trial of an arginineâcontaining formula raised ornithine and was associated with fewer infections and shorter stays (strong clinical signal, formula contained multiple nutrients).
- Early enteral supplementation with key pharmaconutrients improves Sequential Organ Failure Assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double-blind trial
PubMed ID: 18007263
Early enteral pharmaconutrition (multiânutrient) sped organâfunction recovery in sepsis while increasing arginine/ornithine (clinical improvement but multiâcomponent).
- L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial
PubMed ID: 34822189
Large IV LOLA RCT reported greater reductions in ILâ6 and TNFâÎą alongside clinical benefit â suggests some immunomodulatory effect.
Energy & Fatigue (4)
- Randomised controlled trial of the effects of L-ornithine on stress markers and sleep quality in healthy workers
PubMed ID: 24889392
RCT: oral L-ornithine reduced cortisol/DHEA-S ratio and improved sleep/insomnia scores â plausible reduction in fatigue.
- A two-centre, randomized, double-blind trial of ornithine oxoglutarate in 194 elderly, ambulatory, convalescent subjects
PubMed ID: 7976777
Large RCT in elderly: OGO improved appetite, weight and independenceâlikely reduces fatigue.
- A randomized controlled trial of the influence of the mode of enteral ornithine alpha-ketoglutarate administration in burn patients
PubMed ID: 9482764
OKG reduced catabolism in burns and sped recoveryâconsistent with less fatigue.
- Nutritional and clinical efficacy of ornithine alpha-ketoglutarate in severe burn patients
PubMed ID: 10601539
Severe burn patients on OKG preserved weight and improved nutrition, which would reduce fatigue.
Muscle growth (4)
- A randomized controlled trial of the influence of the mode of enteral ornithine alpha-ketoglutarate administration in burn patients
PubMed ID: 9482764
Enteral OKG improved nitrogen balance and reduced muscle catabolism markers in burn patients.
- Nutritional and clinical efficacy of ornithine alpha-ketoglutarate in severe burn patients
PubMed ID: 10601539
Severe burn RCT: OKG produced large cumulative nitrogen balance improvements and higher visceral proteins.
- Ornithine alpha-ketoglutarate improves wound healing in severe burn patients: a prospective randomized double-blind trial versus isonitrogenous controls
PubMed ID: 10890617
OKG decreased markers of hypercatabolism and improved nutritional indices in burn patients.
- A two-centre, randomized, double-blind trial of ornithine oxoglutarate in 194 elderly, ambulatory, convalescent subjects
PubMed ID: 7976777
OGO improved appetite and body weight in elderly convalescentsâconsistent with better protein/nutritional balance.
Mood balance (2)
- A two-centre, randomized, double-blind trial of ornithine oxoglutarate in 194 elderly, ambulatory, convalescent subjects
PubMed ID: 7976777
Improved independence/qualityâofâlife in elderly trial suggests mood benefits.
- Randomised controlled trial of the effects of L-ornithine on stress markers and sleep quality in healthy workers
PubMed ID: 24889392
RCT: L-ornithine reduced anger-hostility (POMS) and improved some mood indices alongside better sleep and lower cortisol ratio.
Muscle soreness (2)
- A randomized controlled trial of the influence of the mode of enteral ornithine alpha-ketoglutarate administration in burn patients
PubMed ID: 9482764
OKG reduced markers of muscle catabolism in burn patientsâplausibly reduces soreness.
- Nutritional and clinical efficacy of ornithine alpha-ketoglutarate in severe burn patients
PubMed ID: 10601539
Severe burn patients on OKG showed reduced catabolism and preserved weightâconsistent with less muscle damage/soreness.
Sleep quality (1)
- Randomised controlled trial of the effects of L-ornithine on stress markers and sleep quality in healthy workers
PubMed ID: 24889392
Randomized double-blind trial: oral L-ornithine for 8 weeks improved insomnia scores (AIS/OSA-MA) and lowered cortisol/DHEA-S ratio.
Stress & Anxiety (1)
- Randomised controlled trial of the effects of L-ornithine on stress markers and sleep quality in healthy workers
PubMed ID: 24889392
8-week oral L-ornithine RCT: significant reduction in serum cortisol/DHEA-S ratio and improvements in sleep and some mood scores â strong evidence for reduced physiological stress.
Forms of Ornithine
The form a label may print instead of Ornithine. Each is a different substance with its own identifier, and none of them has research of its own â the studies are the ones on this page.
Similar by evidence
Supplements the same benefits carry qualifying findings for â a fact about the evidence graph, not a recommendation to swap.
Products with Ornithine
Search all86 products whose verified label declares Ornithine â not every bottle that mentions it in a title.